-
Article
Open AccessAn unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leadi...
-
Article
Open AccessValidation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
Standardized measures for evaluating patients’ experiences with nonalcoholic steatohepatitis (NASH) and their perceived changes with treatment in clinical trials have been limited. To meet this need, a patient...
-
Article
Open AccessA proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
Non-alcoholic fatty liver disease (NAFLD) is a common, progressive liver disease strongly associated with the metabolic syndrome. It is unclear how progression of NAFLD towards cirrhosis translates into system...
-
Article
A researcher’s guide to preclinical mouse NASH models
Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver disease in the Western world and are ris...
-
Article
A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation
Nonalcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver disease. Using a proxy NAFLD definition of chronic elevation of alanine aminotransferase (cALT) levels without other liver diseases,...
-
Article
Advancing the global public health agenda for NAFLD: a consensus statement
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-rang...
-
Article
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is often associated with aspects of metabolic syndrome. Despite its prevalence and the importance of early diagno...
-
Article
Defining comprehensive models of care for NAFLD
Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of chronic liver disease globally. Despite the increased demand placed on health-care systems, little attention has been given to the design a...
-
Article
Open AccessDevelopment of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study
Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease characterized by excessive liver fat accumulation, inflammation, cell injury, and fibrosis. It is viewed as large...
-
Article
Open AccessA molecular signature for the metabolic syndrome by urine metabolomics
Metabolic syndrome (MetS) is a multimorbid long-term condition without consensual medical definition and a diagnostic based on compatible symptomatology. Here we have investigated the molecular signature of Me...
-
Article
Open AccessNASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stra...
-
Article
Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis
Non-alcoholic steatohepatitis (NASH) is characterized by lipotoxicity, inflammation and fibrosis, ultimately leading to end-stage liver disease. The molecular mechanisms promoting NASH are poorly understood, a...
-
Article
From NASH to HCC: current concepts and future challenges
Caloric excess and sedentary lifestyle have led to a global epidemic of obesity and metabolic syndrome. The hepatic consequence of metabolic syndrome and obesity, nonalcoholic fatty liver disease (NAFLD), is e...
-
Article
Author Correction: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
In this Article, the sentence: “After 7 months of HFD, MUP-uPA mice developed HCC15, which contained numerous (usually 50–100 per tumour) non-recurrent coding mutations in pathways that are mutated in human HCC (...
-
Article
Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) is a common, progressive liver disease that affects up to one-quarter of the adult population worldwide. The clinical and economic burden of NAFLD is mainly due to live...
-
Article
Open AccessApplication of long single-stranded DNA donors in genome editing: generation and validation of mouse mutants
Recent advances in clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing have led to the use of long single-stranded DNA (lssDNA) molecules for ge...
-
Article
Open AccessThrombin and factor Xa link the coagulation system with liver fibrosis
Thrombin activates hepatic stellate cells via protease-activated receptor-1. The role of Factor Xa (FXa) in hepatic fibrosis has not been elucidated. We aimed to evaluate the impact of FXa and thrombin in vitr...
-
Article
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
As a consequence of the pandemic spread of obesity, NAFLD is one of the most important causes of liver disease worldwide in adults and children, although some ...
-
Article
Erratum: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Nature 551, 340–345 (2017); doi:10.1038/nature24302 In this Article, owing to an error during the production process, the text ‘(Iga is also known as Cd79a)’ was erroneously added to the sentence describing th...
-
Article
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
IgA+ B cells expressing programmed death ligand 1 (PD-L1) and interleukin 10 accumulate in the inflamed livers of humans and mice with non-alcoholic fatty liver disease where they promote the progression to hepat...
